A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Navitoclax (Primary) ; Bendamustine; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms NAVIGATE
  • Sponsors Genentech
  • Most Recent Events

    • 31 May 2013 Planned End Date changed from 1 May 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Additional locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top